Successful treatment of brain aspergillosis with voriconazole

21Citations
Citations of this article
21Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Until recently, brain aspergillosis was almost always fatal, with a response rate to amphotericin B of < 10%. This study describes a retrospective analysis of eight consecutive cases of brain aspergillosis. All patients were immunosuppressed and five required mechanical ventilation. Antifungal treatment included amphotericin B (n = 7), itraconazole (n = 3), voriconazole (n = 2) and flucytosine (n = 1). Three (38%) patients survived following prolonged azole therapy after initial amphotericin B treatment, combined with a reduction in their immunosuppressive treatment. The prognosis of brain aspergillosis might be improved if immunosuppression could be reduced and prolonged oral azole therapy used. © 2004 Copyright by the European Society of Clinical Microbiology and Infectious Diseases.

Cite

CITATION STYLE

APA

Tattevin, P., Bruneel, F., Lellouche, F., de Broucker, T., Chevret, S., Wolff, M., & Régnier, B. (2004). Successful treatment of brain aspergillosis with voriconazole. Clinical Microbiology and Infection, 10(10), 928–931. https://doi.org/10.1111/j.1469-0691.2004.00981.x

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free